Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade (PAD) vs VAD in Relapsed/Refractory Multiple Myeloma
NCT00441168Phase 2
Key facts
- Status
- Terminated
- Start
- Dec 2006
- Primary completion
- Jan 2008
- Countries
- 7
- Sponsor
- Janssen Pharmaceutical
- Modality
- Small Molecules, Modified Peptides
- Drugs
- bortezomib
- Conditions
- multiple myeloma (MM)
01
Overview
Phase 2, randomised, open-label trial of bortezomib in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Best Confirmed Disease Response and Best Reported Disease Response. Started Dec 2006; status: terminated.
02
Design
2 arms- Study design
- RandomizedOpen-label
PAD Treatment
Bortezomib + Doxorubicin + Dexamethasone
VAD Treatment
Vincristine + Doxorubicin + Dexamethasone
03
Who it enrols
Patients with relapsed or refractory multiple myeloma who have received exactly one prior line of therapy and are suitable for VAD therapy.
04
Endpoints
Primary
Best Confirmed Disease Response
Best Reported Disease Response
Secondary
Duration of Response
Beyond the preview
Go deeper on NCT00441168.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00441168.